{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T13:26:16Z","timestamp":1750771576969},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1097\/mbc.0000000000000088","type":"journal-article","created":{"date-parts":[[2014,2,7]],"date-time":"2014-02-07T09:49:46Z","timestamp":1391766586000},"page":"464-470","source":"Crossref","is-referenced-by-count":7,"title":["Selected parameters of hemostasis in patients with myeloproliferative neoplasms"],"prefix":"10.1097","volume":"25","author":[{"given":"Gra\u017cyna","family":"Gadomska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danuta","family":"Ro\u015b\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Stankowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Boinska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Ruszkowska-Ciastek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rados\u0142aw","family":"Wiecz\u00f3r","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-10-20210203","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","article-title":"Some speculations on the myeloproliferative syndromes.","volume":"6","author":"Dameshek","year":"1951","journal-title":"Blood"},{"key":"R3-10-20210203","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification myeloid neoplasms and acute leukemia: rationale and important changes.","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"R4-10-20210203","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/asheducation-2011.1.257","article-title":"Eosinophilic myeloproliferative disorders.","volume":"2011","author":"Klion Amy","year":"2011","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"R5-10-20210203","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/leu.2008.253","article-title":"Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation.","volume":"22","author":"Landolfi","year":"2008","journal-title":"Leukemia"},{"key":"R6-10-20210203","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.3324\/haematol.2009.013375","article-title":"Blood cell activation in myeloproliferative neoplasms.","volume":"94","author":"Cervantes","year":"2009","journal-title":"Haematologica"},{"key":"R7-10-20210203","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3324\/haematol.2010.038299","article-title":"Pathophysiology of thrombosis in myeloproliferative neoplasms.","volume":"96","author":"Landolfi","year":"2011","journal-title":"Haematologica"},{"key":"R8-10-20210203","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1182\/blood-2008-06-164087","article-title":"Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera.","volume":"112","author":"Marchetti","year":"2008","journal-title":"Blood"},{"key":"R9-10-20210203","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3892\/or_00000674","article-title":"Molecular markers guide diagnosis and treatment in Philadelphia chromosome-negative myeloproliferative disorders (Review).","volume":"23","author":"Vladareanu","year":"2010","journal-title":"Oncol Rep"},{"key":"R10-10-20210203","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/leu.2011.314","article-title":"Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera.","volume":"26","author":"Reikvam","year":"2012","journal-title":"Leukemia"},{"key":"R11-10-20210203","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/0049-3848(94)90226-7","article-title":"High plasma levels of plasminogen activator inhibitor 1 (PAI-1) in polycythemia vera and essential thrombocythemia are associated with thrombosis.","volume":"75","author":"Cancelas","year":"1994","journal-title":"Thromb Res"},{"key":"R12-10-20210203","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1023\/A:1008907001042","article-title":"Clinical implications of elevated PAI-1 revisited: mutiple arterial thrombosis in patient with essential thrombocythemia and elevated plasminogen activator inhibitor-1 (PAI-1) levels: a case report and revive of the literature.","volume":"8","author":"Senno","year":"1999","journal-title":"J Thromb Thrombolysis"},{"key":"R13-10-20210203","first-page":"25","article-title":"Plasminogenesis in blood of patients with chronic myeloproliferative syndromes.","volume":"115","author":"Rosc","year":"2006","journal-title":"Pol Arch Med Wewn"},{"key":"R14-10-20210203","first-page":"138","article-title":"Hemostatic disturbances in chronic myeloid leukemia.","volume":"60","author":"Rosc","year":"2007","journal-title":"Wiad Lek"},{"key":"R15-10-20210203","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/sj.neo.7900184","article-title":"The hemostatic system and angiogenesis in malignancy.","volume":"3","author":"Wojtukiewicz","year":"2001","journal-title":"Neoplasia"},{"key":"R16-10-20210203","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1538-7836.2007.02464.x","article-title":"Fibrinolysis, inflammation, and regulation of the plasminogen activating system.","volume":"5","author":"Medcalf","year":"2007","journal-title":"J Thromb Haemost"},{"key":"R18-10-20210203","first-page":"877","article-title":"Cancer related thrombophilia: clinical importance and management strategies.","volume":"53","author":"Gupta","year":"2005","journal-title":"J Assoc Physicians India"},{"key":"R19-10-20210203","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000175156","article-title":"The plasminogen activator system and cancer.","volume":"36","author":"McMahon","year":"2008","journal-title":"Pathophysiol Haemost Thromb"},{"key":"R20-10-20210203","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.beha.2008.12.005","article-title":"Disseminated intravascular coagulation in cancer patients.","volume":"22","author":"Levi","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"R21-10-20210203","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1161\/ATVBAHA.110.213371","article-title":"Hypercoagulability and hypofibrinolysis and risk of deep vein thrombosis and splachnic vein thrombosis: similarities and differences.","volume":"31","author":"Smalberg","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R22-10-20210203","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s12156-007-0003-7","article-title":"Thrombosis and bleeding in cancer patients.","volume":"1","author":"Kwaan","year":"2007","journal-title":"Oncol Rev"},{"key":"R23-10-20210203","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0001-5814(12)33004-1","article-title":"Haemostasis disturbances in polycythemia vera and essential thrombocythemia.","volume":"43","author":"Szumowska","year":"2012","journal-title":"Acta Haematol Pol"},{"key":"R24-10-20210203","first-page":"51","article-title":"Spontaneus proliferative megakaryocytopoiesis and platelet hyperreactivity in essential thrombocythemia: is thrombopoietin the link Ann H","volume":"79","author":"Bellucci","year":"2000","journal-title":"ematol"},{"key":"R25-10-20210203","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/10428199609074363","article-title":"Bleeding time and platelet function in essential thrombocythemia and other myeloproliferative syndromes.","volume":"22","author":"Finazzi","year":"1996","journal-title":"Leuk Lymph"},{"key":"R26-10-20210203","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood.V96.13.4261","article-title":"Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera.","volume":"96","author":"Falanga","year":"2000","journal-title":"Blood"},{"key":"R27-10-20210203","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.beha.2005.07.011","article-title":"Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention.","volume":"19","author":"Landolfi","year":"2006","journal-title":"Best Pract Res Clin Haematol"},{"key":"R28-10-20210203","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ccc.2009.09.006","article-title":"Hematological issues in critically ill patients with cancer.","volume":"26","author":"Karen","year":"2010","journal-title":"Crit Care Clin"}],"container-title":["Blood Coagulation & Fibrinolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MBC.0000000000000088","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:21:44Z","timestamp":1620958904000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001721-201407000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/mbc.0000000000000088","relation":{},"ISSN":["0957-5235"],"issn-type":[{"value":"0957-5235","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]}}}